Adicet Bio, Inc. Other Comprehensive Income (Loss), Net of Tax
Adicet Bio, Inc. (ACET) reported Other Comprehensive Income (Loss), Net of Tax of -$68.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$68.00K.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$139.00K.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $97.00K, a 19.83% decline year-over-year.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$32.00K.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $86.00K, a 437.50% increase from fiscal 2024.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $16.00K.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for fiscal 2021 was -$24.00K, a 2500.00% decline from fiscal 2020.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax for fiscal 2020 was $1.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$68.00K 10-Q · filed 2026-08-05 | -$207.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$139.00K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $86.00K 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $97.00K 10-Q · filed 2025-11-05 | $65.00K derived: sum of 2 quarters · filed 2026-08-05 | $40.00K derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$32.00K 10-Q · filed 2026-08-05 | -$57.00K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$25.00K 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $16.00K 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $121.00K 10-Q · filed 2025-11-05 | |||
| 2021-12-31 | -$24.00K 10-K · filed 2023-03-15 | |||
| 2021-06-30 | -$2.00K 10-Q · filed 2022-11-08 | -$24.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | -$22.00K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $1.00K 10-K · filed 2022-03-15 | |||
| 2020-09-30 | -$114.00K 10-Q · filed 2021-11-10 | $75.00K derived: sum of 2 quarters · filed 2021-11-10 | $60.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $189.00K 10-Q · filed 2021-11-10 | $174.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | -$15.00K 10-Q · filed 2021-11-10 | |||
| 2019-09-30 | -$5.00K 10-Q · filed 2020-11-05 | -$7.00K derived: sum of 2 quarters · filed 2020-11-05 | $11.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | -$2.00K 10-Q · filed 2020-11-05 | $16.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $18.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |